Similar articles for PMID: 22020909

Year	Number of Results
1997	3
1998	3
1999	11
2000	6
2001	8
2002	4
2003	12
2004	7
2005	6
2006	12
2007	14
2008	10
2009	15
2010	25
2011	37
2012	32
2013	36
2014	29
2015	23
2016	11
2017	6
2018	7
2019	3
2020	4
2022	2
2024	0

1

Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.

Miyasaka A, Kumagai I, Abe K, Suzuki K. Miyasaka A, et al. Hepatogastroenterology. 2012 May;59(115):794-9. doi: 10.5754/hge11570. Hepatogastroenterology. 2012. PMID: 22020909

2

Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.

Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Kobayashi M, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Med Virol. 2006 Jan;78(1):83-90. doi: 10.1002/jmv.20507. J Med Virol. 2006. PMID: 16299715

3

A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Med Virol. 2009 Mar;81(3):452-8. doi: 10.1002/jmv.21400. J Med Virol. 2009. PMID: 19152407

4

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. Hayashi K, et al. Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23. Liver Int. 2011. PMID: 21745312

5

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.

Murayama M, Katano Y, Nakano I, Ishigami M, Hayashi K, Honda T, Hirooka Y, Itoh A, Goto H. Murayama M, et al. J Med Virol. 2007 Jan;79(1):35-40. doi: 10.1002/jmv.20766. J Med Virol. 2007. PMID: 17133546

6

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094. J Med Virol. 2011. PMID: 21503914

7

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Hepatol. 2007 Mar;46(3):403-10. doi: 10.1016/j.jhep.2006.09.019. Epub 2006 Nov 7. J Hepatol. 2007. PMID: 17126448 Clinical Trial.

8

Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, Berg T. Pascu M, et al. Gut. 2004 Sep;53(9):1345-51. doi: 10.1136/gut.2003.031336. Gut. 2004. PMID: 15306598 Free PMC article.

9

Low-dose pegylated interferon-α2a plus ribavirin therapy for elderly and/or cirrhotic patients with HCV genotype-1b and high viral load.

Tamai H, Mori Y, Shingaki N, Kawashima A, Tsukuda H, Higashi K, Moribata K, Kawaguchi M, Ueda K, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Tamai H, et al. Antivir Ther. 2014;19(1):107-15. doi: 10.3851/IMP2696. Epub 2013 Oct 25. Antivir Ther. 2014. PMID: 24162072

10

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Akuta N, et al. J Med Virol. 2012 Jul;84(7):1097-105. doi: 10.1002/jmv.23262. J Med Virol. 2012. PMID: 22585728

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

293 results

Results by year